The prognosis of Indian childhood cirrhosis (ICC) is poor. 1 Of cases presenting to the King Edward Memorial Hospital in Pune in 1979 and 1980, 45% died within four weeks, 74% within eight weeks, and 86% within six months.2 Suggested treatment has included steroids and gammaglobulins,3 levamisole,4 and several traditional and 'ayurvedic' medicines. The copper chelating agent penicillamine is an obvious option for treatment because of the gross hepatic copper accumulation that is characteristic of ICC.5 6 The poor results of chelation treatment in patients with childhood Wilson's disease who presented with advanced disease,7 however, suggested that penicillamine could prove disappointing in ICC as most cases present at a very advanced stage. A proper trial of penicillamine was therefore indicated to forestall the introduction of an expensive, potentially toxic, and possibly ineffective treatment.
Two trials were conducted: the first included a number of advanced cases, and results were poor. This led to a second trial to which only patients who had not progressed to the development of jaundice or ascites were admitted. In this second trial a third treatment group received prednisolone in addition to penicillamine; the rationale for the steroids was their reported efficacy by other workers,7 the inflammatory component of the hepatic pathology,8 and the possibility that lysosomal membrane stabilisation could limit copper cytotoxicity.
Subjects and methods
Children admitted to the King Edward Memorial Hospital in Pune in whom ICC was clinically diagnosed underwent percutaneous liver biopsy if coagulation studies permitted. If the prothrombin time was more than five seconds prolonged parenteral vitamin K and fresh donor blood were given. The Tru-Cut needle (Travenol) was used with local anaesthaesia and sedation with intravenous diazepam.
ICC was diagnosed if histological examination showed that the following features were present9: hepatocyte necrosis, ballooning, and hyaline inclusions; pericellular intralobular fibrosis; and granular orcein staining of hepatocytes.
FIRST TRIAL OF PENICILLAMINE Thirty children with histologically confirmed ICC were studied. The nature and prognosis of the disease were explained to parents and other senior family members before requesting admission to the trial. During the trial other medications such as ayurvedic drugs and liver extracts were stopped. Supportive care comprised nutritional advice and supplementation, treatment of bacterial infections, treatment with vitamin K, avoidance of non-trial medications, and conservative management of liver failure.
Fifteen packs were prepared containing 600 tab-1118
Clinical trials of penicillamine in Indian childhood cirrhosis 1119 lets of 50 mg penicillamine, and 15 packs containing identical placebo tablets. The packs were randomly numbered and were assigned to patients in order of admission to the trial. Children received one tablet of penicillamine or placebo per 2-5 kg/body weight/ day in two doses (equivalent to 20 mg penicillamine/ kg/day). Urinary protein concentration and blood count were monitored weekly for six weeks and thereafter every six weeks where possible. Compliance with treatment was encouraged by repeated home visits by paramedical health workers. In the surviving children a repeat liver biopsy was performed after six weeks if clinically possible. In those children who died in hospital an immediate postmortem liver biopsy was requested. Full autopsy examinations were not permitted by parents.
SECOND TRIAL
Altogether 30 children with ICC were admitted to the trial. The criteria for admission were a histologically confirmed diagnosis of ICC and absence of ascites or jaundice. There were three treatment groups who were given penicillamine, or penicillamine plus prednisolone, or a placebo. The dose of penicillamine was 20 mg/kg/day and of prednisolone 2 mg/kg/day for four weeks and thereafter 5 mg/day. Packs containing the drug(s) or placebos were randomly numbered and allocated to patients in order of presentation. In children surviving for more than three months the treatment code was broken and treatment continued with the medication the child was found to be taking.
In the interval between designing the trial and the trial packs becoming available in Pune children who would have met the admission criteria for the trial were treated with penicillamine, penicillamine and prednisolone, or vitamins (placebo) in a manner that was not blind but strictly in rotation.
In survivors of the trial penicillamine was continued until the histology of the liver was normal and hepatic copper concentrations had returned to normal. 17-1 (2-2) 20-9 (2-2) 
(1) 73 ( *Jaundice or ascites were absent at presentation but became apparent before treatment was started.
group Thirteen children who were eligible for admission to the second trial but who presented before the treatment packs were available were allocated to treatment groups in rotation. Inclusion of these children (five treated with penicillamine, four (table 3) .
Taking all the 29 children treated with penicillamine or penicillamine and prednisolone, a comparison was made between the 14 who survived and the 15 who died to determine whether there were features at entry to the trial that could have predicted a better outcome. Five of 15 non-survivors developed jaundice between presentation and the start of treatment. Non-survivors had larger spleens, higher serum bilirubin concentrations, longer prothrombin times, and higher hepatic copper concentrations, although these differences did not achieve significance (table 4) .
There were 33 liver biopsies performed at follow up in the 14 surviving children. Because of the distance of their homes from Pune and the reluctance of their parents to allow further stays in hospital after clinical improvement biopsies were performed irregularly but all children had one follow up examination and six had three. While five of 14 biopsy specimens taken within six months of starting treatment still showed features of ICC a transition was seen in successive biopsy specimens through the following stages: (i) cirrhosis with thick septae and continued inflammatory infiltration; (ii) inactive micronodular cirrhosis with thin septae, no inflammation, and healthy parenchyma; (iii) incomplete fibrous septae partially dividing a healthy parenchyma; and (iv) almost normal appearances with mild portal fibrosis. At the latest follow up three children had almost normal biopsy specimens, six had incomplete fibrous septae, and five had inactive micronodular cirrhosis.
The concentration of copper in the liver fell at varying rates in different children and was <100 ,ug/g dry weight in only five of the 12 biopsy specimens taken seven to 36 months after starting treatment (table 5) .
Discussion
Before conducting the first trial careful consideration was given to the need for a placebo group. Because of continuing controversy as to the definition and prognosis of ICC' published data would not form an accurate comparison with the treated group. Cases of ICC previously treated in Pune were also not acceptable because the trial protocol included a standard of supportive care that was provided without charge to the family, and which had not previously been available.2 For the second trial, in which the cases were by definition at a less advanced stage of the disease, data as to prognosis without treatment did not exist, and so a placebo group was again necessary. As a difference between treated and untreated cases appeared, termination of the trial was considered. Interim results were presented for discussion at two scientific meetings and continuation of the trial to achieve significance was urged by those taking part. 13 The significantly improved survival in patients treated with penicillamine seen in the second trial now makes it unacceptable for any future trial of penicillamine to include a placebo group. The untreated children in this study show the grim prognosis and fulminant course of ICC. Even those children who did not have ascites or jaundice at presentation declined rapidly, 13 of 14 dying within 165 days. Before the first trial the mortality of ICC In the presence of penicillamine, prednisolone has not been shown to confer additional benefit. Conversely, it was not associated with adverse effects, and with the completion of the trial it was decided to continue treatment of preicteric cases with penicillamine either with or without prednisolone in alternate allocation to see whether there is a difference from larger patient groups. As the number of children treated with penicillamine increases it will become possible to define more accurately favourable and unfavourable prognostic features (table 4) by discriminant analysis.
The clinical recovery from ICC was associated with progressive improvement in histology. These results (to be presented in more detail elsewhere) showed a progressive evolution from ICC to: (i) active cirrhosis with thick inflammatory septae; (ii) inactive micronodular cirrhosis; and (iii) an apparently normal parenchyma with thin fibrous septae. There are few other diseases in which established cirrhosis has been shown to be reversible. The evolution of ICC to inactive micronodular cirrhosis raises the possibility that some children with cryptogenic cirrhosis who are older than those with ICC at presentation may have had a similar aetiology. The occurrence of ICC and inactive micronodular cirrhosis in siblings and a history of copper ingestion in infancy in some cases of inactive micronodular cirrhosis support this conclusion. '9 While ICC may be totally preventable by change in feeding practices in infancy, the present results indicate that treatment of preicteric patients with penicillamine improves survival from 10% to Indian childhood cirrhosis. 
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